Core Viewpoint - WuXi Biologics and Hanchor Bio, Inc. have signed a strategic cooperation agreement to jointly advance the development and production of next-generation bispecific and multispecific antibodies [1][7]. Group 1: Strategic Cooperation - The agreement entails WuXi Biologics providing end-to-end integrated services for biopharmaceutical development and production, including cell line development, process and bioassay development, formulation development, and GMP production [2][9]. - The collaboration aims to accelerate clinical translation processes, enhance CMC execution efficiency, and support Hanchor Bio's innovative fusion protein product portfolio based on the Fc-based design biopharmaceutical (FBDB™) platform for global scale development and production [4][12]. Group 2: Company Background - Hanchor Bio, established in December 2020, is a global clinical-stage biotechnology company focused on developing next-generation immunotherapies for oncology and autoimmune diseases [4][12]. - The FBDB™ platform supports the design of multifunctional biopharmaceuticals with diverse targeting mechanisms, aiming to activate both innate and adaptive immune pathways to overcome challenges associated with current anti-PD1/L1 immunotherapies [4][12]. - Hanchor Bio successfully provided proof-of-concept data in multiple in vivo tumor animal models using the FBDB™ platform [4][12]. - In September of the previous year, Hanchor Bio completed a capital increase of 160 million RMB to accelerate the development of multiple new drugs [4][12].